| Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > SPX: Comparisons of 1994 and 2006 |
|
Answers - SPX: Comparisons of 1994 and 2006
Currently, there's uncertainty if the economy will fall into recession within a year (e.g. given s According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ome of the previous money supply tightenings are in the "pipeline," and the flattening of the yiel ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in d curve). In 1994-95, the Federal Reserve achieved a "soft-landing," and may avert another recessi lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. on in the current period. The first chart is an SPX 1993-94 daily chart that shows a top in Febur here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ary '94, a 9.7% fall in two-months, and then a general uptrend. The second chart is an SPX current d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro daily chart that shows a top three-months ago. The vertical line in the first chart is where SPX ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc was three-months after the '94 top. There are some crude similarites between the two charts, incl easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi uding falling to bottoms quickly, making higher highs and higher lows, and the 50-day MAs falling nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically below the 200-day MAs. The two arrows, in the first chart, indicate a more sustainable rally above and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ the 50-day MA, which began to rise. Consequently, it's uncertain if SPX is currently in a similar ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi uptrend. The third chart shows intermediate-term technical indicators remain bullish (the CPC 50 ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a -day MA, i.e. Put/Call above chart, is particularly bullish, because it peaked at 1.08, which is a dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod n all-time high). However, short-term technical indicators are overbought. SPX 1,261 is key suppor cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin t, i.e. breakout point of mid-July high, middle of daily Bollinger Band, and rising 50-day MA. SPX tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen resistance is around 1,290, i.e. June high. If the FOMC pauses Tuesday, that may ignite a rally, t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel perhaps to around 1,290. However, it may be short-lived, because of concerns about a contracting ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust housing market contributing to higher unemployment, lower consumption, and accelerating inflation y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products (since rents are rising). Also, oil prices remain high. If the Fed tightens, a steep market fall m . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ay take place. Consequently, volatility may continue. Free charts available at elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ref="http://www.peaktrader.com">http://www.peaktrader.com Forum Index Market Forecast category tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Multiple Skills for the 21st Century New To Sales Management? - How To Quickly Establish Authority Credit Repair, Doing it Yourself
|